Home > Healthcare > Pharmaceuticals > Finished Drug Form > Leuprolide Acetate Market
Leuprolide Acetate Market Analysis
- Report ID: GMI5432
- Published Date: Feb 2023
- Report Format: PDF
Leuprolide Acetate Market Analysis
Based on product form, the leuprolide acetate market is categorized into lyophilized powder, vials, and pre-filled syringes. The pre-filled syringes segment was worth over USD 910 million in 2022. The rising consumer demand due to reduced patient risk and the growing knowledge pertaining to the advantages of prefilled syringes, including low tie and money investment, is pushing doctors to utilize pre-filled syringes, which is foreseen to bolster product uptake. To cite an instance, in April 2022, the Lupron Depot 7.5 mg was made available in a prefilled dual-chamber syringe for monthly intramuscular injection that reported less than 5% of patient reactions without any casualties in a clinical trial.
In terms of application, the leuprolide acetate market is segmented into cancer, radical prostatectomy, central precocious puberty, endometriosis, hormone therapy, uterine fibroids, and others. The cancer segment held more than 25% revenue share in 2022. The global surge in cancer cases is increasing the demand for leuprolide acetate drugs for treatment, thereby aiding segment expansion. As per the World Health Organization (WHO), cancer caused over 10 million deaths in 2020. Moreover, the strong prevalence of prostate cancer among men is also set to fuel product adoption.
Leuprolide acetate market from intradermal route of administration segment is projected to exhibit over 5.5% CAGR from 2023 to 2032 as a result of the increasing uptake of hormone therapy. The ID injection route has the longest absorption duration among all parenteral techniques, and is thus, widely used in TB tests, hormone therapy, local anesthetic, and sensitivity tests for allergies. A November 2021 clinical study about the advantages of intradermal tests on patients with allergic rhinitis, asthma, or otitis media found that IDT amplified the chances of successful treatment with no therapeutic failure in 371 patients, helping detect patients who could benefit from allergy immunotherapy.
Based on distribution channel, the leuprolide acetate market is classified into retail pharmacy, hospital pharmacy, and online pharmacy. The online pharmacy segment is primed to depict more than 6% CAGR over the forecast period. The segment growth is attributed to growing patient inclination toward online shopping, particularly after the COVID-19 outbreak. Wide reachability for patients and the inclusion of cutting-edge products are boosting the prominence of e-commerce platforms. In a recent instance, in December 2021, DiRx, a U.S.-based online pharmacy, raised about USD 10 million in Series A funding to broaden its presence in the nation.
North America leuprolide acetate market held more than 39% industry share in 2022. Rising incidences of cancer are providing lucrative expansion opportunities for the regional business. Moreover, a favorable landscape for product approval from regulatory bodies, such as the U.S. FDA, is further supporting regional market growth. To cite an instance, in June 2022, Eugia Pharma Specialty Limited, an API-specific subsidiary of Aurobindo Pharma Ltd., received U.S. FDA approval for its leuprolide acetate injection kit.
Frequently Asked Questions (FAQ) :
Leuprolide Acetate Market Scope
